



	Full Name (Art. 3(2))	HCPs: City of Principal Practice/HCOs: city where registered (Art. 3)	Country of principal practice (Lithuania) (1)	Principal Practice Address (Art. 3)	Lithuanian Identifier (OPTICOM) (Art. 3)	Denominations and Grants to HCOs (Art. 3(1)(a))	Contributions to costs of studies (Art. 3(1)(a) & 3(1)(b))				For the overall development (Art. 3(1)(a) & 3(1)(b))				Total options	
							Sponsorship agreements with HCOs (Total public expenditure) (HCOs % of amount in Euro)	Regulatory Fees (Development)	Trial & Recruitment	Other	Related expenses agreed to by the holder in relation to consultancy contracts, including travel & accommodation related to the contract	Other	Other	Other		
HCPs	No Data Available															
	where information cannot be disclosed on an individual basis for legal reasons															
	Aggregate amount attributable to numbers of sales to each Recipient - Art. 3(2)						0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Number of Recipients to aggregate disclosure - Art. 3(2)						0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HCOs	No Data Available															
	where information cannot be disclosed on an individual basis for legal reasons															
	Total R&D amount attributable to numbers of sales to each Recipient - Art. 3(2)						0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Number of Recipients to aggregate disclosure - Art. 3(2)						0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
R&D	Aggregate disclosure															
	Number of sales to Research & Development as defined - Article 3(4) and Schedule 1															
<b>EPPIA Member Associations</b> The Innovative Pharmaceutical Industry Association (EPPIA) <a href="http://www.eppia.lt">www.eppia.lt</a>																